$CBIS To enroll in this observational study, pleas
Post# of 85277
"The release of CBIS' Unisex Suppository Regimen is an important milestone as we build the company's portfolio of cannabinoid-based medicines. While this regimen is intended for men and women, we expect to release gender-specific suppositories and other products in the near future," stated Mr. Raymond C. Dabney, CBIS' President & CEO and Co-founder.
http://www.marketwired.com/press-release/cann...215769.htm